Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: A retrospective study of three cases from a single centre and literature review

Clinical and Experimental Rheumatology

Volumn 32, Issue 6, 2014, Pages 864-868

  Calvo Río, Vanesa ^a   de la Hera, David ^a   Blanco, Ricardo ^a   Beltrán Catalán, Emma ^b   Loricera, Javier ^a   Cañal, Joaquín ^a   Ventosa, Juan ^a   Cifrián, José M ^a   Ortiz Sanjuán, Francisco ^a   Rueda Gotor, Javier ^a   González Vela, M Carmen ^a   González López, Marcos ^a   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Anti TNF agent; Golimumab; Immune mediated diseases; Uveitis

Indexed keywords

ADALIMUMAB; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CATARACT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EYE DISEASE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; IRIDO LENTICULAR SYNECHIAE; LOADING DRUG DOSE; MACULAR EDEMA; MALE; PRIORITY JOURNAL; PSORIASIS; RECURRENCE RISK; RETINA DETACHMENT; RETROSPECTIVE STUDY; SARCOIDOSIS; SPAIN; TRABECULOTOMY; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UVEITIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; IMMUNOLOGY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84925284272     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. SMIT RL, BAARSMA GS: Epidemiology of uveitis. Curr Opin Ophthalmol 1995; 6: 57-61.
2. CHANG JH, WAKEFIELD D: Uveitis: a global perspective. Ocul Immunol Inflamm 2002; 10: 263-79.
3. DÍAZ-LLOPIS M, SALOM D, GARCIA-DEVICUÑA C et al.: Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-81.
4. MURRAY PI, SIVARAJ RR: Anti-TNF-alpha therapy for uveitis: Behçet and beyond. Eye (Lond) 2005; 19: 831-8.
5. SANTOS LACOMBA M, MARCOS MARTÍN C, GALLARDO GALERA JM et al.: Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res 2001; 33: 251-5.
6. PÉREZ-GUIJO V, SANTOS-LACOMBA M, SÁNCHEZ-HERNÁNDEZ M et al.: Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004; 20: 155-7.
7. NAKAMURA S, SUGITA M, TANAKA T, OHNO S: Enhanced production of in vitro tumor necrosis factor-α from monocytes in Behçet's disease. Nihon Ganka Gakkai Zasshi 1992; 96: 1282-85.
8. POSARELLI C, ARAPI I, FIGUS M, NERI P: Biologic agents in inflammatory eye disease. J Ophthalmic Vis Res 2011; 6: 309-16).
9. WECHSLER B, SABLÉ-FOURTASSOU R, BOD-AGHI B et al.: Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S14-S16.
10. LECCESE P, LATANZA L, D'ANGELO S, PADULA A, OLIVIERI I: Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S93.
11. NERI P, EANDI C, ARAPI I, POSARELLI C, MARIOTTI C, GIOVANNINI A: Long-term Long-term control of non-infectious paediatric panuveitis refractory to traditional immunesuppressive therapy, successfully treated with Adalimumab (HumiraTM). Clin Exp Rheumatol 2013; 31: 458-62.
12. KAY J, RAHMAN MU: Golimumab: a novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 2010; 4: 159-70.
13. SMOLEN JS, KAY J, DOYLE MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
14. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis. Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
15. WILLIAM M, FAEZ S, PAPALIODIS GN, LOBO AM: Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2012; 2: 231-3.
16. CORDERO-COMA M, SALOM D, DÍAZLLOPIS M, LÓPEZ-PRATS MJ, CALLEJA S: Golimumab for uveitis. Ophthalmology 2011; 118: 1892.
17. MISEROCCHI E, MODORATI G, PONTIKAKI I, MERONI P, GERLONI V: Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 2013; 31: 320-1.
18. MESQUIDA M, VICTORIA HERNÁNDEZ M, LLORENÇ V et al.: Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2013; 21: 160-2.
19. DESCHENES J, MURRAY PI, RAO NA, NUSSENBLATT RB: International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16: 1-2.
20. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
21. SOBRIN L, KIM EC, CHRISTEN W, PAPADAKI T, LETKO E, FOSTER CS: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125: 895-900.
22. EMERY P, FLEISCHMANN R, van der HEIJDE D et al.: The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011; 63: 1200-10.
23. KAVANAUGH A, McINNES I, MEASE P et al.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-86.
24. INMAN RD, DAVIS JC JR, HEIJDE D et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
25. SCHOELS M, ALETAHA D, SMOLEN JS, WONG JB: Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-8.
26. ASH Z, EMERY P: Golimumab - a new tool in the armoury against inflammatory arthritis. Ann Med 2011; 43: 133-41.